Double-blind crossover study on the protective effect of fenoterol--administered by pressurized aerosol and in powder form--in allergen-induced asthma.
The purpose of this study was to determine the level of protection afforded by fenoterol (200 microgram), administered by pressurized aerosol, in allergen-induced bronchospasm and to compare its effect with that of the same drug administered at the same dosage in powder form. It was a double-blind crossover study on 14 patients with atopic asthma. The administration of the drug took place at weekly intervals according to an appropriate randomized schedule. The sensitizing allergen was inhaled 30 min after the administration of the drug. Parameters of the respiratory function were controlled at fixed intervals over a 2-hour period. The study showed that both fenoterol formulations possess a protective effect in allergen-induced bronchospasm. No statistically significant difference between the two types of drug preparation (pressurized aerosol and powder form) was observed regarding the individual measuring times. In an overall evaluation, statistically significant differences between dry powder and pressurized aerosol have been observed.
D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy*; D001985:Bronchial Provocation Tests; D001986:Bronchial Spasm / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004983:Ethanolamines / Q000627:therapeutic use*; D005280:Fenoterol / Q000627:therapeutic use*; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D011208:Powders; D012130:Respiratory Hypersensitivity / Q000188:drug therapy*
D000336:Aerosols; D004983:Ethanolamines; D011208:Powders; D005280:Fenoterol